Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer

Promoter hypermethylation is a major mechanism for gene silencing and offers a promising starting point for developing molecular biomarkers. The purpose of our study was to determine aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A with respect to its prevalence and quantitative level in bronchial aspirates from patients with suspected lung cancer. Applying quantitative methylation‐specific PCR, 155 bronchial aspirates from patients with non‐small cell cancer (NSCLC) and small cell cancer (SCLC) of the lung as well as 67 bronchial aspirates from patients diagnosed for nonneoplastic lung disease were examined in a retrospective case‐control study. Aberrant APC promoter 1A methylation was seen in 71% of NSCLCs, 38% of SCLCs and 42% of patients with nonneoplastic lung disease, being therefore not specific for the presence of primary lung cancer. In contrast, quantitative analysis showed a significantly higher methylation level of bronchial aspirates from NSCLC as compared to patients without neoplastic lung disease. Introducing a cutoff point that defined high level of APC hypermethylation NSCLC could be discriminated from cases without neoplastic disease with a specificity of 98.5% and a sensitivity of 39%. The data suggest that quantitative analysis of APC hypermethylation may serve as a biomarker of primary lung cancer. © 2004 Wiley‐Liss, Inc.

[1]  T. Motoyama,et al.  Promoter hypermethylation of tumor suppressor and tumor‐related genes in non‐small cell lung cancers , 2003, Cancer science.

[2]  T. Motoyama,et al.  Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples , 2003, Oncogene.

[3]  S. Goodman,et al.  Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  J. Minna,et al.  Smoke exposure, histologic type and geography‐related differences in the methylation profiles of non‐small cell lung cancer , 2003, International journal of cancer.

[5]  E. Maher,et al.  Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients , 2003, Oncogene.

[6]  M. Sarbia,et al.  DNA Extraction from Bronchial Aspirates for Molecular Cytology: Which Method to Take? , 2003, Analytical Cellular Pathology.

[7]  J. Minna,et al.  Aberrant DNA methylation in lung cancer: biological and clinical implications. , 2002, The oncologist.

[8]  F. Gilliland,et al.  Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. , 2002, Cancer research.

[9]  Chih-Yi Chen,et al.  Alterations of the p16ink4a gene in resected nonsmall cell lung tumors and exfoliated cells within sputum , 2002, International journal of cancer.

[10]  P. Laird,et al.  Hierarchical clustering of lung cancer cell lines using DNA methylation markers. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  Diane D. Liu,et al.  Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. , 2002, Cancer research.

[12]  D. Sidransky,et al.  Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.

[13]  Thomas D. Schmittgen,et al.  Real-Time Quantitative PCR , 2002 .

[14]  F. Bray,et al.  Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.

[15]  J Herman,et al.  Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  David Sidransky,et al.  Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival , 2001, Oncogene.

[17]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[18]  J. Minna,et al.  5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. , 2001, Cancer research.

[19]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[20]  S. Groshen,et al.  Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. , 2000, Journal of the National Cancer Institute.

[21]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.

[22]  F. Khuri,et al.  Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.

[23]  A. Kraus,et al.  Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Herman,et al.  Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. , 2000, Cancer research.

[25]  S. Nishizuka,et al.  Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia , 2000, Oncogene.

[26]  N. Ahuja,et al.  Aging, methylation and cancer. , 2000, Histology and histopathology.

[27]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[28]  J. Herman,et al.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.

[29]  P. Laird,et al.  CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. , 1999, Cancer research.

[30]  Y. Shimosato,et al.  Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.

[31]  E Gabrielson,et al.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[33]  P. Polakis.  The adenomatous polyposis coli (APC) tumor suppressor. , 1997, Biochimica et biophysica acta.

[34]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Sugimura,et al.  Interaction between cytochrome P-450 2E1 polymorphisms and environmental factors with risk of esophageal and stomach cancers in Chinese. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  J. Minna,et al.  Aberrant promoter methylation of multiple genes in non-small cell lung cancers. , 2001, Cancer research.

[37]  A. Mehta,et al.  Role of Bronchoscopy in Lung Cancer , 2000, Seminars in respiratory and critical care medicine.